Please login to the form below

Not currently logged in
Email:
Password:

Kesimpta

This page shows the latest Kesimpta news and features for those working in and with pharma, biotech and healthcare.

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

Kesimpta was approved in the EU for the treatment of RMS in adults with active disease at the end of March. ... Kesimpta also met the key secondary endpoints, which included delaying time to confirmed disability progression, in the head-to-head study.

Latest news

  • Novartis wins FDA approval for relapsing MS drug Kesimpta Novartis wins FDA approval for relapsing MS drug Kesimpta

    Kesimpta also met the key secondary endpoints, which included delaying time to confirmed disability progression, in the head-to-head study. ... Last May, Novartis’ chief exec Narasimhan identified Kesimpta as one of the company’s potential

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Reaching patients and HCPs during the pandemic Reaching patients and HCPs during the pandemic

    Self-administered injectables, such as Novo Nordisk’s recently approved therapy for adult growth hormone deficiency (GHD), Sogroya (somapacitan), and Novartis’ much-hyped MS treatment, Kesimpta (ofatumumab), will be tested in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics